FI102676B1 - Menetelmä terapeuttisesti käyttökelpoisten 3-amido- ja 3-sulfamidoindolyylijohdannaisten valmistamiseksi - Google Patents

Menetelmä terapeuttisesti käyttökelpoisten 3-amido- ja 3-sulfamidoindolyylijohdannaisten valmistamiseksi

Info

Publication number
FI102676B1
FI102676B1 FI915146A FI915146A FI102676B1 FI 102676 B1 FI102676 B1 FI 102676B1 FI 915146 A FI915146 A FI 915146A FI 915146 A FI915146 A FI 915146A FI 102676 B1 FI102676 B1 FI 102676B1
Authority
FI
Finland
Prior art keywords
amido
sulfamidoindolyl
derivatives
preparation
therapeutically useful
Prior art date
Application number
FI915146A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI102676B (fi
FI915146A0 (fi
FI915146A (fi
Inventor
Francesco Gerald Salituro
Bruce Michael Baron
Original Assignee
Merrell Dow Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharma filed Critical Merrell Dow Pharma
Publication of FI915146A0 publication Critical patent/FI915146A0/fi
Publication of FI915146A publication Critical patent/FI915146A/fi
Application granted granted Critical
Publication of FI102676B publication Critical patent/FI102676B/fi
Publication of FI102676B1 publication Critical patent/FI102676B1/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Paints Or Removers (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
FI915146A 1990-11-02 1991-10-31 Menetelmä terapeuttisesti käyttökelpoisten 3-amido- ja 3-sulfamidoindolyylijohdannaisten valmistamiseksi FI102676B1 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60845790A 1990-11-02 1990-11-02
US76753191A 1991-10-02 1991-10-02

Publications (4)

Publication Number Publication Date
FI915146A0 FI915146A0 (fi) 1991-10-31
FI915146A FI915146A (fi) 1992-05-03
FI102676B FI102676B (fi) 1999-01-29
FI102676B1 true FI102676B1 (fi) 1999-01-29

Family

ID=27085774

Family Applications (1)

Application Number Title Priority Date Filing Date
FI915146A FI102676B1 (fi) 1990-11-02 1991-10-31 Menetelmä terapeuttisesti käyttökelpoisten 3-amido- ja 3-sulfamidoindolyylijohdannaisten valmistamiseksi

Country Status (17)

Country Link
EP (1) EP0483881B1 (de)
JP (1) JP3168565B2 (de)
KR (1) KR100220882B1 (de)
AT (1) ATE162519T1 (de)
AU (1) AU641052B2 (de)
CA (1) CA2054339C (de)
DE (1) DE69128764T2 (de)
DK (1) DK0483881T3 (de)
ES (1) ES2113359T3 (de)
FI (1) FI102676B1 (de)
GR (1) GR3026349T3 (de)
HU (1) HU214597B (de)
IE (1) IE913834A1 (de)
IL (1) IL99908A (de)
NO (1) NO177139C (de)
NZ (1) NZ240380A (de)
PT (1) PT99400B (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4242675A1 (de) * 1992-12-17 1994-06-23 Basf Ag Neue Hydroxyiminoalkylindolcarbonsäure-Derivate, ihre Herstellung und Verwendung
GB9311948D0 (en) * 1993-06-10 1993-07-28 Zeneca Ltd Substituted nitrogen heterocycles
TW280819B (de) * 1993-11-17 1996-07-11 Sumitomo Pharma
US5801168A (en) * 1994-06-09 1998-09-01 Zeneca Limited Substituted nitrogen heterocycles
ATE548031T1 (de) 2000-12-18 2012-03-15 Inst Med Molecular Design Inc Inhibitoren gegen die produktion und freisetzung entzündungfördernder zytokine
SI1470102T1 (sl) * 2002-01-29 2011-08-31 Merck Serono Sa Substituirani derivati metilen amida kot modulatorji proteinskih tirozinskih fosfataz (ptp)
GB0217920D0 (en) * 2002-04-23 2002-09-11 Aventis Pharm Prod Inc Interleukin-4 Gene Expression inhibitors
CN1658872B (zh) 2002-06-06 2010-09-22 株式会社医药分子设计研究所 抗过敏药
KR20110028554A (ko) 2002-06-06 2011-03-18 가부시키가이샤 이야쿠 분지 셋케이 겐쿠쇼 O-치환 히드록시아릴 유도체
JP4635130B2 (ja) * 2002-06-11 2011-02-16 株式会社医薬分子設計研究所 神経変性疾患治療剤
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
CA2570363A1 (en) 2004-06-18 2005-12-29 Biolipox Ab Indoles useful in the treatment of inflammation
ES2310366T3 (es) * 2004-08-24 2009-01-01 Janssen Pharmaceutica Nv Nuevos derivados de heteroaril sulfonamida benzo-condensada utiles como agentes anticonvulsivos.
AU2005325497A1 (en) 2005-01-19 2006-07-27 Biolipox Ab Indoles useful in the treatment of inflammation
AU2006249577A1 (en) 2005-05-20 2006-11-30 Janssen Pharmaceutica N.V. Process for preparation of sulfamide derivatives
RU2419610C2 (ru) 2005-05-26 2011-05-27 Ньюрон Системз, Инк. Композиции и способы лечения заболевания сетчатки
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
AR058389A1 (es) 2005-12-19 2008-01-30 Janssen Pharmaceutica Nv Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
AU2007253814A1 (en) 2006-05-19 2007-11-29 Janssen Pharmaceutica N.V. Co-therapy for the treatment of epilepsy
NZ590682A (en) 2008-06-23 2012-09-28 Janssen Pharmaceutica Nv Crystalline form of (2S)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
JP5885670B2 (ja) 2009-12-11 2016-03-15 アルデイラ セラピューティクス, インコーポレイテッド 黄斑変性の処置のための組成物および方法
KR20150118106A (ko) 2012-12-20 2015-10-21 알데이라 테라퓨틱스, 아이엔씨. 페리-카르비놀
KR102435676B1 (ko) 2013-01-23 2022-08-24 알데이라 테라퓨틱스, 아이엔씨. 독성 알데히드 관련된 질병 및 치료
EP2948436A4 (de) 2013-01-25 2016-07-13 Aldeyra Therapeutics Inc Neuartige fallen bei der behandlung von makuladegeneration
CN118724806A (zh) 2015-08-21 2024-10-01 奥尔德拉医疗公司 氘化化合物和其用途
AU2017264697A1 (en) 2016-05-09 2018-11-22 Aldeyra Therapeutics, Inc. Combination treatment of ocular inflammatory disorders and diseases
WO2018170476A1 (en) 2017-03-16 2018-09-20 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
US11040039B2 (en) 2017-10-10 2021-06-22 Aldeyra Therapeutics, Inc. Treatment of inflammatory disorders
JP2021533154A (ja) 2018-08-06 2021-12-02 アルデイラ セラピューティクス, インコーポレイテッド 多形化合物およびその使用
WO2020223717A1 (en) 2019-05-02 2020-11-05 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
CA3137301A1 (en) 2019-05-02 2020-11-05 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
WO2021231792A1 (en) 2020-05-13 2021-11-18 Aldeyra Therapeutics, Inc. Pharmaceutical formulations and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60123485A (ja) * 1983-12-08 1985-07-02 Yoshitomi Pharmaceut Ind Ltd インド−ル−3−カルボキサミド誘導体
US4675332A (en) * 1984-12-10 1987-06-23 Warner-Lambert Company Acidic tetrazolyl substituted indole compounds and their use as antiallergy agents
NZ222878A (en) * 1986-12-17 1991-02-26 Merck Frosst Canada Inc 3-hetero-substituted-n-benzyl-indole derivatives, and pharmaceutical compositions

Also Published As

Publication number Publication date
ES2113359T3 (es) 1998-05-01
FI102676B (fi) 1999-01-29
ATE162519T1 (de) 1998-02-15
AU8676091A (en) 1992-05-07
FI915146A0 (fi) 1991-10-31
CA2054339A1 (en) 1992-05-03
NO177139C (no) 1995-07-26
HU214597B (hu) 1998-04-28
IL99908A0 (en) 1992-08-18
FI915146A (fi) 1992-05-03
EP0483881B1 (de) 1998-01-21
IL99908A (en) 1995-10-31
JP3168565B2 (ja) 2001-05-21
PT99400A (pt) 1992-09-30
HUT59668A (en) 1992-06-29
KR100220882B1 (ko) 1999-09-15
DE69128764D1 (de) 1998-02-26
DK0483881T3 (da) 1998-03-16
PT99400B (pt) 1999-04-30
AU641052B2 (en) 1993-09-09
HU913454D0 (en) 1992-01-28
KR920009796A (ko) 1992-06-25
IE913834A1 (en) 1992-05-22
NZ240380A (en) 1994-05-26
NO914300L (no) 1992-05-04
NO914300D0 (no) 1991-11-01
EP0483881A1 (de) 1992-05-06
GR3026349T3 (en) 1998-06-30
DE69128764T2 (de) 1998-06-04
NO177139B (no) 1995-04-18
CA2054339C (en) 2002-12-24
JPH0733737A (ja) 1995-02-03

Similar Documents

Publication Publication Date Title
FI102676B1 (fi) Menetelmä terapeuttisesti käyttökelpoisten 3-amido- ja 3-sulfamidoindolyylijohdannaisten valmistamiseksi
FI881103A0 (fi) Menetelmä antidiabeettisena aineena käytettävien bensoksatsolijohdannaisten valmistamiseksi
FI890282A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten 23,24-didehydro-25-hydroksikalsiferolijohdannaisten valmistamiseksi
FI104170B1 (fi) Menetelmä terapeuttisesti käyttökelpoisten 3-amidopyratsolijohdannaisten valmistamiseksi
FI895417A0 (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten 2'-halometylideeninukleosidien valmistamiseksi
FI95701C (fi) Menetelmä terapeuttisesti käyttökelpoisten kromaanijohdannaisten valmistamiseksi
FI914418A0 (fi) Menetelmä 9-substituoitujen guaniinijohdannaisten valmistamiseksi ja välituotteita menetelmässä käytettäväksi
FI925518A (fi) Menetelmä terapeuttisesti aktiivisten 1-piperidinyylialkanoyyliaryylisulfonamidijohdannaisten valmistamiseksi
FI103202B1 (fi) Menetelmä terapeuttisesti käyttökelpoisten 4-sulfonamido-1,4-dihydrokinoliiinijohdannaisten valmistamiseksi
FI97388B (fi) Menetelmä heterosyklisten NMDA-antagonistien valmistamiseksi
ATE143058T1 (de) Typisierung humaner rhinoviren
SE8904189D0 (sv) Anordning foer straeckbehandling av en maenniskas rygg
SE9001671D0 (sv) Preparation process of thieno-triazolo-diazepine derivatives

Legal Events

Date Code Title Description
FG Patent granted

Owner name: MERRELL DOW PHARMACEUTICALS INC.

PC Transfer of assignment of patent

Owner name: AVENTIS INC.

Free format text: AVENTIS INC.

PC Transfer of assignment of patent

Owner name: AVENTISUB II INC.

Free format text: AVENTISUB II INC.

MA Patent expired